Lefitolimod

Drug Profile

Lefitolimod

Alternative Names: MGN-1703

Latest Information Update: 29 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mologen
  • Developer Aarhus Universitetshospital; Mologen; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; DNA
  • Mechanism of Action Immunomodulators; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Colorectal cancer
  • Phase II Small cell lung cancer
  • Phase I/II HIV-1 infections
  • Phase I Solid tumours

Most Recent Events

  • 25 Aug 2017 Mologen signs binding term sheet for licensing agreement with iPharma for lefitolimod in China, Hong Kong, Macau, Taiwan and Singapore and co-development agreement with iPharma for lefitolimod worldwide
  • 11 Aug 2017 Adverse events and efficacy data from extension of the phase I/II trial in HIV-1 infections released by Mologen
  • 09 Aug 2017 Mologen plans a clinical study for HIV-1 infections (Combination therapy) in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top